Clinical Trials Currently Available at
the
University of Kansas Medical Center
I. Breast
Cancer
A. Preventive
B. Early and Advanced
II. Gastrointestinal
Cancer
A. Esophageal
B.
Liver
III.
Genitourinary
Cancer
A. Bladder
B. Prostate
C. Renal
IV. Gynecologic
Cancer
A. Cervical
B. Endometrial
C. Ovarian
D. Sarcoma
E. Vulvar
V. Head
& Neck Cancer
VI. Lung
Cancer
A. Non-Small Cell
B. Small Cell
VII. Melanoma
A. Early
VIII. Hematology
VIIII. Childrens
Oncology Group
IX. Southwest
Oncology Group
I. BREAST CANCER
A. Breast
Cancer Prevention
Study
of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer
Effects
of Selective Estrogen Receptor Modulators on Cognitive Aging:
Cognition in the Study of Tamoxifen and Raloxifene (Co-STAR)
B. Early
and Advanced Breast
Cancer
Phase II Study:
To Assess Efficacy of Tumor Bed Irradiation Only in a Selected Subgroup of
Patients with Early Stage Breast Cancer, KU # 4/96
A Phase II Trial of Neoadjuvant Docetaxel,
Capecitabine + Trastuzumab, Followed by Sequential Adjuvant
Adriamycin/Cytoxan and Trastuzumab in Locally Advanced Breast Cancer
Phase II Trial of Neoadjuvant Docetaxel and Capecitabine in Locally Advanced Breast Cancer
Phase 1B
Randomized Study of the Selective Estrogen Receptor Modulators (SERMs)
Tamoxifen and LY353381HCl, and Placebo, in Postmenopausal Women with
Newly-Diagnosed Breast Cancer
II. GASTROINTESTINAL
A. Esophageal
Cancer
B. Liver
Phase II Study of Gemcitabine Plus Irinotecan Plus Celecoxib in Patients with Hepatobiliary Cancer
III.
GENITOURINARY
A. Bladder
Cancer
MVAC in
Organ-Confined Bladder Cancer Based on p53 Status
B.
Prostate
Taxotere/Ketoconazole/Decadron For
Advanced Prostate Cancer
C.
Renal
IV. GYNECOLOGIC
A. Cervical
Cancer
A Phase II Evaluation of Docetaxel (NSC #628503) in the Treatment of
Persistent or Recurrent Squamous Cell Carcinoma of the Cervix, GOG 127-S
Expression of the
MN Protein in Atypical Glandular Cells of Undetermined Significance (AGUS
or AGCUS) as a Potential Diagnostic Biomarker of Cervical Dysplasia/Neoplasia,
GOG #171
A
Phase III Trial to Evaluate the Efficacy of Maintaining Hemoglobin Levels
Above 120 G/L with Erythropoietin Versus Above 100 G/L Without
Erythropoietin in Anemic Patients Receiving Concurrent Radiation and
Cisplatin for Cervical Cancer, GOG #191
A Phase II Evaluation of Bevacizumab (rhuMAB VEGF) (NSC #704865, IND #7921) in the Treatment of Persistent or Recurrent Squamous Cell Carcinoma of the Cervix, GOG 227-C
B. Endometrial
Cancer
A Phase II Evaluation of Flavopiridol in the Treatment of Recurrent or
Persistent Endometrial Carcinoma, GOG #129-M
A Phase II Trial of ZD 1839 (Iressa™) (NSV #715055, IND #61187) in the Treatment of Persistent or Recurrent Endometrial Carcinoma, GOG 229-C
A Phase II Evaluation of Thalidomide in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus, GOG 230-B
C. Ovarian
Cancer
A Phase II Evaluation of Epothilone-B BMS 247550 in the Treatment of
Recurrent or Persistent Platinum and Paclitaxel Refractory Ovarian or
Primary Peritoneal Cancer, GOG 126-M
A Phase II Evaluation of Bevacizumab (rhuMAB VEGF) (NSC #704865, IND #7921) in the Treatment of Persistent or Recurrent Ovarian and Primary Peritoneal Carcinoma, GOG 170-D
A Randomized
Phase III Trial of IV Carboplatin (AUC 6) and Paclitaxel 175 mg/m2 Q 21
Days X 3 Courses Plus Low Dose Paclitaxel 40 mg/m2/wk Versus IV
Carboplatin (AUC 6) and Paclitaxel 175 mg/m2 Q 21 Days X 3 Courses Plus
Observation in Patients with Early Stage Ovarian Carcinoma, GOG #175
Phase II Study of
Paclitaxel for Ovarian Stromal Tumors as First-Line or Second-Line
Therapy, GOG #187
An Exploratory Evaluation of Fenretinide (4-HPR) as a Chemopreventive Agent for Ovarian Carcinoma, GOG 190
A Randomized Study of Tamoxifen versus Thalidomide (NSC #669847) in Patients with Biochemical Recurrence only Epithelial Ovarian Cancer, Cancer of the Fallopian Tube and Primary Peritoneal Carcinoma After First Line Chemotherapy, GOG 198
Antioxidant Effects in the Treatment of Ovarian Cancer
D. Sarcoma
E. Vulvar
V. HEAD & NECK
Whole Brain Radiation With or Without
Radiosurgery
for 1-3 Cerebral Mestastases, ACOSOG Z0300
VI. LUNG
A. Non-Small
Cell Cancer
B. Small
Cell Cancer
VII. MELANOMA
A. Early
Melanoma
Sunbelt Melanoma
Trial (SMT): A Multicenter Trial of Adjuvant Interferon Alfa-2B for
Melanoma Patients with Early Lymph Node Metastasis Detected by Lymphatic
Mapping and Sentinel Lymph Node Biopsy
VIII. HEMATOLOGY
Doxil® (Pegylated
Liposomal Doxorubicin), Dexamethsone Plus Thalidomide (Ddt) in Previously
Untreated Multiple Myeloma